Compile Data Set for Download or QSAR
Report error Found 43 Enz. Inhib. hit(s) with all data for entry = 10638
Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556317(US11345702, Table 1.35 | US20230390274, Compound A...)
Affinity DataIC50: 0.5nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556286(US11345702, Table 1.4 | US20230390274, Compound A-...)
Affinity DataIC50: 0.600nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556308(US11345702, Table 1.26 | US20230390274, Compound A...)
Affinity DataIC50: 1.5nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556300(US11345702, Table 1.18 | US20230390274, Compound A...)
Affinity DataIC50: 1.80nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556287(US11345702, Table 1.5 | US20230390274, Compound A-...)
Affinity DataIC50: 2.5nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM50445521(CHEMBL3103033 | US11345702, Table 1.21 | US2023039...)
Affinity DataIC50: 2.70nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556325(US11345702, Table 2.8 | US20230390274, Compound A-...)
Affinity DataIC50: 3.10nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556313(US11345702, Table 1.31 | US20230390274, Compound A...)
Affinity DataIC50: 3.10nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556306(US11345702, Table 1.24 | US20230390274, Compound A...)
Affinity DataIC50: 3.20nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556299(US11345702, Table 1.17 | US20230390274, Compound A...)
Affinity DataIC50: 5.20nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556294(US11345702, Table 1.12 | US20230390274, Compound A...)
Affinity DataIC50: 5.60nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556298(US11345702, Table 1.16 | US20230390274, Compound A...)
Affinity DataIC50: 5.70nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556316(US11345702, Table 1.34 | US20230390274, Compound A...)
Affinity DataIC50: 5.80nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM50445514(CHEMBL3103040 | US11345702, Table 1.33 | US2023039...)
Affinity DataIC50: 6.40nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556320(US11345702, Table 2.3 | US20230390274, Compound A-...)
Affinity DataIC50: 8.5nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556309(US11345702, Table 1.27 | US20230390274, Compound A...)
Affinity DataIC50: 10.6nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556301(US11345702, Table 1.19 | US20230390274, Compound A...)
Affinity DataIC50: 12.2nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556311(US11345702, Table 1.29 | US20230390274, Compound A...)
Affinity DataIC50: 12.8nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556322(US11345702, Table 2.5 | US20230390274, Compound A-...)
Affinity DataIC50: 18.6nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556284(US11345702, Table 1.2 | US20230390274, Compound A-...)
Affinity DataIC50: 19.5nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556285(US11345702, Table 1.3 | US20230390274, Compound A-...)
Affinity DataIC50: 20.1nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556307(US11345702, Table 1.25 | US20230390274, Compound A...)
Affinity DataIC50: 24.9nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556323(US11345702, Table 2.6 | US20230390274, Compound A-...)
Affinity DataIC50: 27.1nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556314(US11345702, Table 1.32 | US20230390274, Compound A...)
Affinity DataIC50: 43.7nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556304(US11345702, Table 1.22 | US20230390274, Compound A...)
Affinity DataIC50: 43.9nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556290(US11345702, Table 1.8 | US20230390274, Compound A-...)
Affinity DataIC50: 44.9nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556302(US11345702, Table 1.20 | US20230390274, Compound A...)
Affinity DataIC50: 46.6nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556291(US11345702, Table 1.9 | US20230390274, Compound A-...)
Affinity DataIC50: 47.1nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556312(US11345702, Table 1.30 | US20230390274, Compound A...)
Affinity DataIC50: 49.3nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556283(US11345702, Table 1.1 | US20230390274, Compound A-...)
Affinity DataIC50: 57.4nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556295(US11345702, Table 1.13 | US20230390274, Compound A...)
Affinity DataIC50: 64.7nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556305(US11345702, Table 1.23 | US20230390274, Compound A...)
Affinity DataIC50: 116nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556318(US11345702, Table 2.1 | US20230390274, Compound A-...)
Affinity DataIC50: 135nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556292(US11345702, Table 1.10 | US20230390274, Compound A...)
Affinity DataIC50: 158nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556310(US11345702, Table 1.28 | US20230390274, Compound A...)
Affinity DataIC50: 197nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556296(US11345702, Table 1.14 | US20230390274, Compound A...)
Affinity DataIC50: 274nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556319(US11345702, Table 2.2 | US20230390274, Compound A-...)
Affinity DataIC50: 277nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556297(US11345702, Table 1.15 | US20230390274, Compound T...)
Affinity DataIC50: 576nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556324(US11345702, Table 2.7 | US20230390274, Compound A-...)
Affinity DataIC50: 593nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556288(US11345702, Table 1.6 | US20230390274, Compound A-...)
Affinity DataIC50: 1.26E+3nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556321(US11345702, Table 2.4 | US20230390274, Compound A-...)
Affinity DataIC50: 2.28E+3nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556289(US11345702, Table 1.7 | US20230390274, Compound A-...)
Affinity DataIC50: 2.87E+3nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent

Target15-hydroxyprostaglandin dehydrogenase [NAD(+)](Human)
Myoforte Therapeutics

US Patent
LigandPNGBDBM556293(US11345702, Table 1.11 | US20230390274, Compound A...)
Affinity DataIC50: 4.54E+3nMAssay Description:A hydroxyprostaglandin dehydrogenase inhibition screening biochemical assay can be performed to assess the synthesized inhibitors provided herein. Pr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/5/2022
Entry Details
US Patent